EDWARDS LIFESCIENCES CORPORATION (NYSE:EW) Files An 8-K Results of Operations and Financial ConditionItem 2.02.Results of Operations and Financial Condition.
On February1, 2018, the Company issued a press release announcing its 2017 fourth quarter and full year financial results.The financial information included in the February 1, 2018 press release has been revised to reflect a revision to the Company’s computation of its tax on unremitted foreign earnings for the three and twelve months ended December 31, 2017. A copy of the revised financial information is furnished herewith as Exhibit99.1 and is incorporated herein by reference.
The information provided in this Item 2.02 (including Exhibit99.1) of this Current Report on Form8-K/A is being furnished and shall not be deemed to be “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be deemed to be incorporated by reference in any filing made by Edwards Lifesciences Corporation to the Securities Act of 1933, as amended, or the Exchange Act other than to the extent that such filing incorporates by reference any or all of such information by express reference thereto.
Item 9.01.Financial Statements and Exhibits.
|
(d) |
Exhibits |
|
99.1 |
Revised financial information of Edwards Lifesciences Corporation for the three and twelve months ended December 31, 2017. |
Edwards Lifesciences Corp ExhibitEX-99.1 2 amendedex-991q42017.htm EXHIBIT 99.1 Exhibit EDWARDS LIFESCIENCES CORPORATIONUnaudited Consolidated Statements of Operations(in millions,…To view the full exhibit click here
About EDWARDS LIFESCIENCES CORPORATION (NYSE:EW)
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. The Company conducts operations around the world and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.
